There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CTI BioPharma (CTIC – Research Report) and Atara Biotherapeutics (ATRA – Research Report) with bullish sentiments.
CTI BioPharma (CTIC)
Needham analyst Gil Blum maintained a Buy rating on CTI BioPharma today and set a price target of $5.00. The company’s shares closed last Wednesday at $1.99.
According to TipRanks.com, Blum ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on CTI BioPharma is a Strong Buy with an average price target of $5.55, implying a 155.3% upside from current levels. In a report issued on December 1, JMP Securities also reiterated a Buy rating on the stock with a $4.00 price target.
See today’s best-performing stocks on TipRanks >>
Atara Biotherapeutics (ATRA)
Mizuho Securities analyst Salim Syed maintained a Buy rating on Atara Biotherapeutics today and set a price target of $41.00. The company’s shares closed last Wednesday at $15.32.
According to TipRanks.com, Syed is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atara Biotherapeutics with a $33.00 average price target, representing an 110.7% upside. In a report issued on December 7, William Blair also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CTIC:
